AR055336A1 - Proeso de elaboracion para la produccion de tigeciclina como un polvo reconstituible, polvo de tigeciclina liofilizado y producto hecho mediante el proceso - Google Patents

Proeso de elaboracion para la produccion de tigeciclina como un polvo reconstituible, polvo de tigeciclina liofilizado y producto hecho mediante el proceso

Info

Publication number
AR055336A1
AR055336A1 ARP060102533A ARP060102533A AR055336A1 AR 055336 A1 AR055336 A1 AR 055336A1 AR P060102533 A ARP060102533 A AR P060102533A AR P060102533 A ARP060102533 A AR P060102533A AR 055336 A1 AR055336 A1 AR 055336A1
Authority
AR
Argentina
Prior art keywords
powder
tigecycline
tigecicline
solution
production
Prior art date
Application number
ARP060102533A
Other languages
English (en)
Spanish (es)
Inventor
Gurmukh Chanana
Dominique Ventura
Richard Saunders
Mahdi B Fawzi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR055336A1 publication Critical patent/AR055336A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
    • C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP060102533A 2005-06-16 2006-06-15 Proeso de elaboracion para la produccion de tigeciclina como un polvo reconstituible, polvo de tigeciclina liofilizado y producto hecho mediante el proceso AR055336A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69117305P 2005-06-16 2005-06-16

Publications (1)

Publication Number Publication Date
AR055336A1 true AR055336A1 (es) 2007-08-22

Family

ID=37111782

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102533A AR055336A1 (es) 2005-06-16 2006-06-15 Proeso de elaboracion para la produccion de tigeciclina como un polvo reconstituible, polvo de tigeciclina liofilizado y producto hecho mediante el proceso

Country Status (22)

Country Link
US (1) US7705168B2 (enExample)
EP (1) EP1898884A2 (enExample)
JP (3) JP2008543871A (enExample)
KR (1) KR20080024201A (enExample)
CN (1) CN101198315A (enExample)
AR (1) AR055336A1 (enExample)
AU (1) AU2006261636A1 (enExample)
BR (1) BRPI0612228A2 (enExample)
CA (1) CA2610909A1 (enExample)
CR (1) CR9594A (enExample)
EC (1) ECSP078005A (enExample)
GT (1) GT200600259A (enExample)
IL (1) IL187979A0 (enExample)
MX (1) MX2007015960A (enExample)
NO (1) NO20076264L (enExample)
PA (1) PA8680201A1 (enExample)
PE (1) PE20070072A1 (enExample)
RU (1) RU2007145595A (enExample)
SV (1) SV2007002575A (enExample)
TW (1) TW200716203A (enExample)
WO (1) WO2006138641A2 (enExample)
ZA (1) ZA200710906B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2649221A1 (en) * 2006-04-17 2007-10-25 Evgeny Tsiperman Isolation of tetracycline derivatives
DE202007019460U1 (de) * 2006-04-24 2012-10-24 Teva Pharmaceutical Industries Ltd. Kristalline Tigecyclin-Formen
US8198470B2 (en) * 2006-04-24 2012-06-12 Teva Pharmaceutical Industries Ltd. Crystalline form II of tigecycline and processes for preparation thereof
WO2008066935A2 (en) * 2006-11-29 2008-06-05 Teva Pharmaceutical Industries Ltd. Crystalline forms of tigecycline and processes for preparation thereof
WO2008066908A1 (en) * 2006-11-30 2008-06-05 Teva Pharmaceutical Industries Ltd. Processes for preparation of 9-haloacetamidominocyclines
EP2114865A1 (en) * 2007-03-01 2009-11-11 Teva Pharmaceutical Industries Ltd. Processes for purification of tigecycline
US20090099376A1 (en) * 2007-10-16 2009-04-16 Wyeth Tigecycline and methods of preparing intermediates
US9107929B2 (en) 2008-05-01 2015-08-18 Ranbaxy Laboratories Limited Stable parenteral formulations of tigecycline
ITMI20080807A1 (it) 2008-05-05 2009-11-06 Antibioticos Spa Procedimento per la preparazione di tigeciclina in forma amorfa
US20100035845A1 (en) * 2008-08-06 2010-02-11 Wyeth Tigecycline formulations
PT104350A (pt) 2009-01-23 2010-07-23 Hovione Farmaci Ncia S A Processo de isolamento de tigeciclina
JP2012520305A (ja) 2009-03-12 2012-09-06 ワイス・エルエルシー テトラサイクリンのニトロ化
CN103417498B (zh) * 2012-05-18 2017-09-12 山东新时代药业有限公司 一种替加环素冻干粉针剂的制备方法
IN2013MU01127A (enExample) 2013-03-26 2015-05-01 Astron Res Ltd
WO2014167575A2 (en) 2013-03-26 2014-10-16 Astron Research Limited Stable tigecycline composition
CN103202814A (zh) * 2013-04-23 2013-07-17 成都百裕科技制药有限公司 一种注射用替加环素的制备方法
CN105924367B (zh) * 2016-04-18 2017-12-29 镇江高海生物药业有限公司 多西环素一水物的有关物质及其分析检测方法
WO2019147755A1 (en) * 2018-01-26 2019-08-01 AL Pharma, Inc. Manufacturing and packaging of a sterile drug product
CN108653216B (zh) * 2018-05-28 2020-12-18 福安药业集团湖北人民制药有限公司 注射用替加环素
WO2021063468A1 (en) 2019-10-02 2021-04-08 Anfarm Hellas S.A. Stable parenteral pharmaceutical composition containing tigecycline and process for the preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3026248A (en) * 1959-09-11 1962-03-20 Pfizer & Co C Thioglycerol and formaldehyde sulfoxylate stabilized tetracycline antibiotics in polyhydric alcohol solvents
US5494903A (en) * 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5284963A (en) * 1992-08-13 1994-02-08 American Cyanamid Company Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines
US6660267B1 (en) * 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
US5675030A (en) * 1994-11-16 1997-10-07 American Cyanamid Company Method for selective extracting a 7-(hydrogen or substituted amino)-9- (substituted glycyl) amido!-6-demethyl-6-deoxytetracycline compound
EP1531828A4 (en) * 2002-05-23 2005-11-02 Activbiotics Inc METHODS OF TREATING BACTERIAL INFECTIONS AND ASSOCIATED DISEASES
ATE415973T1 (de) * 2004-10-28 2008-12-15 Wyeth Corp Gemeinsame gabe von tigecyclin und digoxin
KR20130122988A (ko) * 2005-03-14 2013-11-11 와이어쓰 엘엘씨 티게사이클린 조성물 및 이의 제조방법
AR057034A1 (es) 2005-05-27 2007-11-14 Wyeth Corp Metodos para purificar tigeciclina

Also Published As

Publication number Publication date
SV2007002575A (es) 2007-01-03
ECSP078005A (es) 2008-01-23
CN101198315A (zh) 2008-06-11
NO20076264L (no) 2008-03-10
US7705168B2 (en) 2010-04-27
MX2007015960A (es) 2008-03-06
CR9594A (es) 2008-03-07
US20070026080A1 (en) 2007-02-01
WO2006138641A2 (en) 2006-12-28
EP1898884A2 (en) 2008-03-19
BRPI0612228A2 (pt) 2011-03-29
GT200600259A (es) 2007-05-08
PA8680201A1 (es) 2007-01-17
KR20080024201A (ko) 2008-03-17
IL187979A0 (en) 2008-03-20
ZA200710906B (en) 2009-03-25
AU2006261636A1 (en) 2006-12-28
PE20070072A1 (es) 2007-02-25
TW200716203A (en) 2007-05-01
RU2007145595A (ru) 2009-07-27
JP2008543871A (ja) 2008-12-04
WO2006138641A3 (en) 2007-05-18
JP2009191083A (ja) 2009-08-27
JP2010024252A (ja) 2010-02-04
CA2610909A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
AR055336A1 (es) Proeso de elaboracion para la produccion de tigeciclina como un polvo reconstituible, polvo de tigeciclina liofilizado y producto hecho mediante el proceso
TWI237570B (en) New method for obtaining aqueous formulations with active principles susceptible to oxidation and the aqueous solutions thus obtained
FI4011377T3 (fi) Suonensisäinen infuusioannosmuoto sisältäen pemetreksediä
JP2008543871A5 (enExample)
DE60309731D1 (de) Injizierbare pharmazeutische suspension in einer phiole mit zwei kammern
US20150190509A1 (en) Resiniferatoxin solution
RU2011140749A (ru) Устройство для интраназального введения
EP2389923B1 (en) Stable ready to use injectable paracetamol formulation
PE20090838A1 (es) Pontenciacion de quimioterapia de cancer
CN105979949B (zh) 不含抗氧化剂的药物组合物及其制备方法
JP6244608B2 (ja) 水素含有エアゾールおよび該水素含有エアゾールの保管方法
EP2920106B1 (en) A method for filling bottles
EA201171440A1 (ru) Способ ароматизации размещаемого в упаковке пищевого продукта
CA3051924C (en) GLASS LED ASSEMBLY
WO2009081283A2 (en) Aqueous formulations of acetaminophen for injection
ES2445871T3 (es) Procedimiento para el almacenamiento y para el transporte de diésteres cíclicos
AR124867A1 (es) Un medicamento en una bolsa de goteo intravenoso plegable lista para usar herméticamente sellada, método para hacer dicho medicamento y medicamento elaborado mediante dicho método
JP6150703B2 (ja) ピタバスタチンカルシウム塩の分解抑制方法
ME01745B (me) NOVA STABILNA HIPERBARIČNA KOMPOZICIJA KOJA SADRŽI PRILOKAIN HCL,PRIMENA NAVEDENE NOVE KOMPOZICIJE ZA INTRATEKALNU ANESTEZIJU l POSTUPAK ZA PROIZVODNJU NAVEDENE KOMPOZICIJE
RU2017146440A (ru) Способ получения лекарственного средства на основе олигопептида аллоферона-1, имеющего противовирусную и иммуномодулирующую направленность и лекарственное средство увеличенного срока хранения, полученное с его помощью
AU2006203741A1 (en) Method for obtaining aqueous formulations with active principles susceptible to oxidation and the aqueous solutions thus obtained
Tóth Methadone overdose Fatal toxicity: case report
JP2017105857A (ja) 注射液製剤及びその製造方法
MX2008009272A (en) Stabilization of paricalcitol using chlorobutyl or chlorinated butyl stoppers
JP6384992B2 (ja) ロスバスタチンカルシウムの安定性を向上させた保存方法

Legal Events

Date Code Title Description
FB Suspension of granting procedure